World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
65237
World Ranking
8111
National Ranking
4206

Overview

David L. Porter is affiliated with the University of Pennsylvania in the United States. Their research primarily focuses on the field of medicine, with particular emphasis on oncology, hematology, genetics, molecular biology, and immunology. Within these areas, their work extensively covers CAR-T cell therapy research, acute myeloid leukemia research, virus-based gene therapy research, hematopoietic stem cell transplantation, viral infectious diseases and gene expression in insects, lymphoma diagnosis and treatment, as well as integrated circuits and semiconductor failure analysis.

The scientist's publication record includes recent papers reflecting ongoing contributions to hematologic malignancies and cellular therapies. Notable recent publications include:

  • "Decade-long leukaemia remissions with persistence of CD4+ CAR T cells" (2022, Nature)
  • "Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy" (2022, Nature Medicine)
  • "T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy" (2024, Nature Medicine)
  • "Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies" (2020, Journal of Allergy and Clinical Immunology)
  • "Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia" (2020, Journal of Clinical Oncology)

Frequent co-authors with whom David L. Porter has collaborated include Noelle V. Frey, Stephen J. Schuster, Elizabeth O. Hexner, Saar Gill, and Alison W. Loren.

Publication venues where this scientist commonly publishes research work include:

  • Blood
  • Transplantation and Cellular Therapy
  • Blood Advances
  • Nature Medicine
  • Hematological Oncology

Best Publications

  • Chimeric antigen receptor T cells for sustained remissions in leukemia.

    Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc

  • Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

  • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

    Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

  • T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

  • Current concepts in the diagnosis and management of cytokine release syndrome

    Daniel W. Lee;Rebecca Gardner;David L. Porter;Chrystal U. Louis

  • Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    Stephen J. Schuster;Jakub Svoboda;Elise A. Chong;Sunita D. Nasta

  • Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

    David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey

  • Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    Joseph A. Fraietta;Simon F. Lacey;Elena J. Orlando;Iulian Pruteanu-Malinici

  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    R H Collins;O Shpilberg;W R Drobyski;D L Porter

  • Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

    David T. Teachey;David T. Teachey;Simon F. Lacey;Pamela A. Shaw;J. Joseph Melenhorst

  • Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

    Claudio Anasetti;Brent R. Logan;Stephanie J. Lee;Edmund K. Waller

  • Antibody-modified T cells: CARs take the front seat for hematologic malignancies

    Marcela V. Maus;Stephan A. Grupp;Stephan A. Grupp;David L. Porter;Carl H. June

  • Use of chimeric antigen receptor-modified t cells to treat cancer

    Carl H. June;Bruce L. Levine;David L. Porter;Michael D. Kalos

  • Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

    Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

  • CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

    Shannon L. Maude;David T. Teachey;David L. Porter;Stephan A. Grupp;Stephan A. Grupp

  • Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

    David L. Porter;Mark S. Roth;Carol McGarigle;James Ferrara

  • Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    Stefan O. Ciurea;Mei Jie Zhang;Andrea A. Bacigalupo;Asad Bashey

  • International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

    Andrew C. Harris;Andrew C. Harris;Rachel Young;Rachel Young;Steven Devine;William J. Hogan

  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

    Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Bart L. Scott;Marcelo C. Pasquini;Brent R. Logan;Juan Wu

Frequent Co-Authors

Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
Carl H. June
Carl H. June University of Pennsylvania
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Simon F. Lacey
Simon F. Lacey University of Pennsylvania
J. Joseph Melenhorst
J. Joseph Melenhorst University of Pennsylvania
Michael Kalos
Michael Kalos Next Pillar Consulting
David M. Barrett
David M. Barrett Children's Hospital of Philadelphia
David T. Teachey
David T. Teachey Children's Hospital of Philadelphia
Michael C. Milone
Michael C. Milone University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees is an increasingly popular way to advance in the healthcare field, particularly for those interested in roles beyond traditional MD/DO programs. Many students choose to pursue options like dnp online programs to become doctorally-prepared nurses while maintaining work-life balance. These flexible programs often allow for accelerated completion, helping graduates access specialized and leadership roles more quickly.

For those mindful of costs, the cheapest dnp program offerings can ease financial pressures and expand access to advanced nursing practice. Additionally, if your goal is faster entry into nursing, lpn fast track program options provide expedited pathways to become a Licensed Practical Nurse—ideal for career changers or anyone seeking to quickly start working in healthcare.

Mental health careers are also in high demand. The psych np online programs offer rigorous yet flexible training for those aiming to specialize as psychiatric mental health nurse practitioners. As the healthcare landscape evolves, these alternative online degrees and fast-track pathways can open diverse career opportunities for those passionate about medicine and patient care.

Best Scientists Citing David L. Porter

Trending Scientists

Recently Published Articles